

Richter and Fuji strengthen strategic collaboration in women healthcare segment

February 5, 2026 | News

Joint efforts in business development and R&D within gynecology, a strategic priority area for both parties



Budapest-based Gedeon Richter Plc. and Japan's Fuji Pharma Co. have announced the expansion and further strengthening of their long-standing strategic collaboration.

The two companies have had a strong partnership in Women's Healthcare (WHC). This collaboration is exemplified by Fuji's development, launch, and marketing in Japan of Alyssa[®], a dysmenorrhea treatment containing drospirenone and estetrol (E4), as well as by the commercialisation of the oral contraceptive Nextstellis[™] in Thailand.

Fuji also holds rights to commercialise Richter's estetrol (E4)-based hormone replacement therapy candidate in Japan and ASEAN territories. This product candidate has recently received a positive opinion from CHMP (Committee for Medicinal Products for Human Use) in Europe under the brand name FYLREVVY[®].

Investment and innovation in women's healthcare remain insufficient. Globally, research and development in this area is estimated to account for less than five percent of overall pharmaceutical R&D, resulting in limited treatment options for the future, and at the same time creating opportunities for innovative companies willing to invest. Against this backdrop, Richter and Fuji have signed a Business Collaboration Agreement that will strengthen joint efforts in business development and R&D within gynecology, a strategic priority area for both parties.

Leveraging the experience and expertise each organization has cultivated, the partnership will jointly identify, assess, and pursue the acquisition or in-licensing of promising external drug candidates worldwide. Together with internal projects, these initiatives aim to accelerate innovation and deliver advanced therapeutic solutions in women's health globally.

To promote innovation in gynecology, Richter has recently established an original research hub for drug discovery and development in Belgium as well as strengthened its Budapest-based R&D activities. This hub will play a pivotal role in advancing the joint development efforts of Richter and Fuji.